Liver cirrhosis, a late-stage liver disease, is characterized by fibrosis and the formation of regenerative nodules. It is a significant global health issue with a multitude of complications that require comprehensive management strategies.
Portal hypertension is a frequent complication of cirrhosis, often leading to varices and ascites. Management includes beta-blockers for primary prophylaxis and endoscopic band ligation for secondary prophylaxis of variceal bleeding. Diuretics and sodium restriction are primary treatment options for ascites.
Hepatic encephalopathy (HE), characterized by cognitive impairment and altered consciousness, is another common complication. Lactulose and rifaximin are the mainstays of therapy. Early detection and treatment of precipitating factors, such as infections and gastrointestinal bleeding, are crucial.
Hepatorenal syndrome (HRS) is a severe complication characterized by renal failure in the absence of kidney disease. Albumin and vasoconstrictors, such as terlipressin, are the first-line treatment. Renal replacement therapy and liver transplantation may be required in severe cases.
Hepatocellular carcinoma (HCC) is a leading cause of death in cirrhotic patients. Surveillance with ultrasound and alpha-fetoprotein levels is recommended every six months. Treatment options include surgical resection, liver transplantation, and locoregional therapies.
Managing complications of liver cirrhosis requires a comprehensive, multidisciplinary approach. Early recognition and prompt management of these complications can significantly improve patient outcomes. It is crucial for healthcare professionals to stay updated on the latest therapeutic strategies to provide optimal patient care.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation